.png "Axsome Therapeutics Inc (NASDAQ: AXSM)")
H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Axsome Therapeutics Inc (NASDAQ: AXSM) today and set a price target of $10. The company’s shares closed yesterday at $2.30, close to its 52-week low of $2.05.
According to TipRanks.com, Selvaraju has 0 stars on 0-5 star ranking scale with an average return of -3.9% and a 35.2% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as IntelliPharmaCeutics International, Biospecifics Technologies Corp, and EyePoint Pharmaceuticals Inc.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Axsome Therapeutics Inc with a $10 average price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $6.45 and a one-year low of $2.05. Currently, Axsome Therapeutics Inc has an average volume of 144.8K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Axsome Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in developing novel therapies for the management of central nervous system disorders. Its product candidates include AXS-02 and AXS-06 which are developing for multiple indications.
